Result of Oncology Ventures Drug Response Prediction for TKI drug from Big Pharma available in third week of January 2018

Hoersholm, Denmark, December 14th, 2017 – Oncology Venture AB (OV:ST) announces updated timeline for receiving results of the patient response prediction (DRP) for an undisclosed small molecule, kinase inhibitor (TKI) from Novartis Pharma AG (Basel, Switzerland) which has been in phase 3 in renal cancer patients. The initial report performed by Novartis is expected to be available and communicated in third week of January. The timeline for this publication has previously been communicated as 6-8 weeks from the 23 October 2017. The analysis of the tumor tissue is performed by a third party on the behalf of Novartis and the evaluation of the DRP’s ability to predict which patients had positive outcome of the treatment is done by Novartis.

In July 2017 Oncology Venture entered into an agreement with Novartis providing Oncology Venture with an option right to execute an exclusive license to develop and commercialize an undisclosed small molecule, multi tyrosine kinase inhibitor in clinical development. The molecule has been explored in multiple clinical trials in several cancer indications including a variety of solid tumors.

“I look very much forward to receive this independent analysis of our prediction – we do have a very strong pipeline of active products – however the Novartis TKI is an advanced and very exciting opportunity and a positive outcome could have major impact on Oncology Venture” said Peter Buhl Jensen, M.D., CEO of Oncology Venture.

For further information, please contact

About the Drug Response Predictor (DRP®) Companion Diagnostic

Oncology Venture uses the Medical Prognosis Institute (MPI) multi gene DRP® technology to select those patients that, by the genetic signature in their cancer, is found to have a high likelihood of response to a given drug. The goal is to develop the drug for the right patients by screening patients before treatment, whereby the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP® is based on messenger RNA from the patients’ biopsies. The DRP® platform (i.e. the DRP® and the PRP™ biomarkers) can be used in all cancer types, and is patented for more than 70 anti-cancer drugs in the US. The PRP™ is commercialized by MPI for Personalized Medicine. The DRP® is commercialized by Oncology Venture for drug development.

About Oncology Venture Sweden AB 

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP®) technology in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP® and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop the Novartis small molecule kinase inhibitor.

This information is that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 14th 2017.